Skip to main content
. 2017 Aug 11;8(46):80560–80567. doi: 10.18632/oncotarget.20156

Figure 1. MMP-2 in lung cancer patients and benign diseases.

Figure 1

(A) Comparison of MMP-2 levels in BALF between lung cancer and control group. The levels of MMP-2 were significantly higher in lung cancer patients than those in controls (**P < 0.01). (B) Representative examples of immunohistochemistry of MMP-2 expression in human lung specimens. (C) Quantification of MMP-2 expression in the lung cancer and benign diseases (***P < 0.001). (D) In subgroup analysis by tumor histology, BALF MMP-2 remained significantly higher in different cell types of lung cancer patients than benign controls. (E) BALF MMP-2 concentration were assessed according to TNM stage. Values in the box plot are given as median (interquartile range); BALF, bronchoalveolar lavage fluid; SCC, squamous cell carcinoma; ADC, adenocarcinoma; SCLC, small-cell lung cancer.